Advertisement

Drugs & Aging

, Volume 23, Issue 10, pp 795–805 | Cite as

Treatment of Benign Prostatic Hyperplasia in Patients with Cardiovascular Disease

  • Vincent M. Santillo
  • Franklin C. Lowe
Therapy In Practice

Abstract

Pharmacological management is the most common therapeutic approach for patients with benign prostatic hyperplasia and α-adrenoceptor antagonists are the most commonly prescribed initial treatment. Although all of the α-adrenoceptor antagonists produce similar improvements in symptom scores and urinary flow rates, they have different adverse effect profiles, especially with respect to the cardiovascular system. The older α-adrenoceptor antagonists, terazosin and doxazosin, were initially approved for the treatment of hypertension and are associated with higher rates of dizziness, syncope and hypotension than the newer agents, tamsulosin and alfuzosin. The older α-adrenoceptor antagonists are also involved in more interactions and have a greater number of precautions concerning their usage with other cardiovascular medications. Of the newer α-adrenoceptor antagonists, tamsulosin has a lower rate of dizziness than alfuzosin. However, both of these agents are superior to doxazosin and terazosin in that no dose escalation or titration is needed for them.

Keywords

Benign Prostatic Hyperplasia Lower Urinary Tract Symptom Finasteride Tamsulosin Doxazosin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Dr Franklin Lowe has been a consultant for Boehringer-Ingelheim and has received honoraria for lecturing from Boehringer-Ingelheim, Sanofi and Schering/Gallaxo. Dr Vincent Santillo has no potential conflicts of interest that are directly relevant to the content of this article. No sources of funding were used in the preparation of this article.

References

  1. 1.
    Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan Jr ED, Wein AJ, editors. Campbell’s urology. 8th ed. Philadelphia (PA): Saunders, 2002: 1297–330Google Scholar
  2. 2.
    Lowe FC. Role of the newer alphal-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 2004 Nov; 26(11): 1701–13PubMedCrossRefGoogle Scholar
  3. 3.
    Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006 Jan; 28(1): 13–25PubMedCrossRefGoogle Scholar
  4. 4.
    AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003 Aug; 170 (2 Pt 1): 530–47CrossRefGoogle Scholar
  5. 5.
    Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984 Sep; 132(3): 474–9PubMedGoogle Scholar
  6. 6.
    Fagelman E, Lowe FC. Herbal medications in the treatment of benign prostatic hyperplasia (BPH). Urol Clin North Am 2002 Feb; 29(1): 23–9PubMedCrossRefGoogle Scholar
  7. 7.
    Santillo VS, Lowe FC. Phytotherapeutic agents for the treatment of benign prostatic hyperplasia. AUA Update Series. In pressGoogle Scholar
  8. 8.
    Dreikorn K. The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia. World J Urol 2002 Apr; 19(6): 426–35PubMedGoogle Scholar
  9. 9.
    Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 2002 Jan; 12(1): 15–8PubMedCrossRefGoogle Scholar
  10. 10.
    Fitzpatrick JM, Desgrandchamps F. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. BJU Int 2005 Mar; 95(4): 575–9PubMedCrossRefGoogle Scholar
  11. 11.
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published erratum appears in JAMA 2003 Jul 9; 290 (2): 197]. JAMA 2003 May 21; 289(19): 2560–72PubMedCrossRefGoogle Scholar
  12. 12.
    ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000 Apr; 283(15): 1967–75CrossRefGoogle Scholar
  13. 13.
    McConnell JD, Mahler C, Calais da Dilva F, et al. Endocrine treatment of benign prostatic hyperplasia. In: Chatelain C, Denis L, Foo KT, et al., editors. Benign prostatic hyperplasia. Proceedings of the 5th International Consultation on Benign Prostatic Hyperplasia (BPH); 2000 Jun 25–28; Paris. Plymouth: Plymbridge Distributors Ltd, 2001: 425–57Google Scholar
  14. 14.
    Kirby RS, Bryan J, Eardley I, et al. Finasteride in the treatment of benign prostatic hyperplasia: a urodynamic evaluation. Br J Urol 1992 Jul; 70(1): 65–72PubMedCrossRefGoogle Scholar
  15. 15.
    Marks LS, Partin AW, Gormley GJ, et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol 1997 Jun; 157(6): 2171–8PubMedCrossRefGoogle Scholar
  16. 16.
    Marks LS, Partin AW, Dorey FJ, et al. Long-term effects of finasteride on prostate tissue composition. Urology 1999 Mar; 53(3): 574–80PubMedCrossRefGoogle Scholar
  17. 17.
    Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004 Apr; 63(4): 709–15PubMedCrossRefGoogle Scholar
  18. 18.
    Kaplan SA, Neutel J. Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology 2006 Feb; 67(2): 225–31PubMedCrossRefGoogle Scholar
  19. 19.
    Jardin A, Andersson K-E, Chapple C, et al. α1-Adrenoceptor antagonists in the treatment of BPH. In: Chatelain C, Denis L, Foo KT, et al., editors. Benign prostatic hyperplasia. Proceedings of the 5th International Consultation on Benign Prostatic Hyperplasia (BPH); 2000 Jun 25–28; Paris. Plymouth: Plymbridge Distributors Ltd, 2001: 461–77Google Scholar
  20. 20.
    Roehrborn CG, Schwinn DA. Alphal-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004 Mar; 171(3): 1029–35PubMedCrossRefGoogle Scholar
  21. 21.
    Kawabe K. Current status of research on prostate-selective alpha 1-antagonists. Br J Urol 1998 Mar; 81Suppl. 1: 48–50PubMedGoogle Scholar
  22. 22.
    Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 1996 Nov; 119(5): 797–803PubMedCrossRefGoogle Scholar
  23. 23.
    Waiden PD, Gerardi C, Lepor H. Localization and expression of the alphalA-1, alphalB and alphalD-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 1999 Feb; 161(2): 635–40CrossRefGoogle Scholar
  24. 24.
    Rudner XL, Berkowitz DE, Booth JV, et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 1999 Dec; 100(23): 2336–43PubMedCrossRefGoogle Scholar
  25. 25.
    Kyprianou N, Litvak JP, Borkowski A, et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998 Jun; 159(6): 1810–5PubMedCrossRefGoogle Scholar
  26. 26.
    Chon JK, Borkowski A, Partin AW, et al. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1999 Jun; 161(6): 2002–8PubMedCrossRefGoogle Scholar
  27. 27.
    Partin JV, Anglin IE, Kyprianou N. Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer 2003 May 19; 88(10): 1615–21PubMedCrossRefGoogle Scholar
  28. 28.
    Akduman B, Crawford ED. Terazosin, doxazosin, and prazosin: current clinical experience. Urology 2001 Dec; 58 (6 Suppl. 1): 49–54PubMedCrossRefGoogle Scholar
  29. 29.
    Roehrborn CG. Three months’ treatment with the alpha(1)-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis. Epub 2005 Nov 22Google Scholar
  30. 30.
    Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996 Aug 22; 335(8): 533–9PubMedCrossRefGoogle Scholar
  31. 31.
    Nieminen T, Ylitalo R, Koobi T, et al. The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: a randomised, double-blind, placebo-controlled study. Eur Urol 2005 Mar; 47(3): 340–5PubMedCrossRefGoogle Scholar
  32. 32.
    Roehrborn CG. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology 2001 Dec; 58 (6 Suppl. 1): 55–63PubMedCrossRefGoogle Scholar
  33. 33.
    Weiner DM, Lowe FC. Alfuzosin for the management of benign prostate hyperplasia. Expert Opin Pharmacother 2003 Nov; 4(11): 2057–63PubMedCrossRefGoogle Scholar
  34. 34.
    Mottet N, Bressolle F, Delmas V, et al. Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur Urol 2003 Jul; 44(1): 101–5PubMedCrossRefGoogle Scholar
  35. 35.
    Basar MM, Atan A, Ozergin O, et al. The efficacy of alfuzosin treatment in patients with prostatism. Int Urol Nephrol 2001; 33(3): 493–7PubMedCrossRefGoogle Scholar
  36. 36.
    Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997 Jul–Aug; 19(4): 730–42PubMedCrossRefGoogle Scholar
  37. 37.
    AUA Practice Guidelines Committee. AUA Guideline on the Management of Benign Prostatic Hyperplasia (2003). Chapter 3: Results of the treatment outcomes analyses [online]. Available from URL: http://www.auanet.org/timssnet/products/guidelines/main_reports/bph_management/chapt_3_appendix.pdf [Accessed 2006 Mar 1]Google Scholar
  38. 38.
    Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006 Jan; 28(1): 13–25PubMedCrossRefGoogle Scholar
  39. 39.
    Elhilali M, Emberton M, Matzkin H, et al. Long-term efficacy and safety of alfuzosin 10mg once daily: a 2-year experience in’ real-life’ practice. BJU Int 2006 Mar; 97(3): 513–9PubMedCrossRefGoogle Scholar
  40. 40.
    McKiernan JM, Lowe FC. Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South Med J 1997 May; 90(5): 509–13PubMedCrossRefGoogle Scholar
  41. 41.
    Narayan P, Lowe FC. The effects of tamsulosin on vital signs in two multicenter, placebo-controlled studies. Cardiovasc Rev Rep 2000; 21: 494–9Google Scholar
  42. 42.
    Lowe FC, Olson PJ, Padley RJ. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. Urology 1999 Jul; 54(1): 81–5PubMedCrossRefGoogle Scholar
  43. 43.
    Guthrie RM, Siegel RL. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). Clin Ther 1999 Oct; 21(10): 1732–48PubMedCrossRefGoogle Scholar
  44. 44.
    Kaplan SA, D’Alisera PM. Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies. J Gerontol A Biol Sci Med Sci 1998 May; 53(3): M201–6PubMedCrossRefGoogle Scholar
  45. 45.
    Buzelin JM, Fonteyne E, Kontturi M, et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol 1997 Oct; 80(4): 597–605PubMedCrossRefGoogle Scholar
  46. 46.
    Lowe FC, Djavan B. Prospective randomized trial to evaluate the side effect profile of tamsulosin versus terazosin in 1983 men with benign prostatic hyperplasia [abstract no. 1052]. J Urol 2002; 167 (4S): 267Google Scholar
  47. 47.
    Nordling J. Efficacy and safety of two doses (10 and 15mg) of alfuzosin or tamsulosin (0.4mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005 May; 95(7): 1006–12PubMedCrossRefGoogle Scholar
  48. 48.
    Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. J Urol 2000 Apr; 163(4): 1134–7PubMedCrossRefGoogle Scholar
  49. 49.
    Crawford ED. Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile. BJU Int 2005 Jun; 95Suppl. 4: 1–5PubMedCrossRefGoogle Scholar
  50. 50.
    Souverein PC, Herings RM, de la Rosette JJ, et al. Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations. J Clin Epidemiol 2001 May; 54(5): 518–24PubMedCrossRefGoogle Scholar
  51. 51.
    Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001 Sep; 54(9): 935–44PubMedCrossRefGoogle Scholar
  52. 52.
    Roehrborn CG, Oesterling JE, Auerbach S, et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996 Feb; 47(2): 159–68PubMedCrossRefGoogle Scholar
  53. 53.
    Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994 Jul; 44(1): 46–51PubMedCrossRefGoogle Scholar
  54. 54.
    Pool JL. Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials. Am Heart J 1991 Sep; 122 (3 Pt 2): 926–31PubMedCrossRefGoogle Scholar
  55. 55.
    Chapple CR, Baert L, Thind P, et al. Tamsulosin 0.4mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol 1997; 32(4): 462–70PubMedGoogle Scholar
  56. 56.
    Michel MC, Bressel HU, Goepel M, et al. A 6-month large-scale study into the safety of tamsulosin. Br J Clin Pharmacol 2001 Jun; 51(6): 609–14PubMedCrossRefGoogle Scholar
  57. 57.
    Michel MC, Chapple CR. Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). Eur Urol 2006 Mar; 49(3): 501–8PubMedCrossRefGoogle Scholar
  58. 58.
    Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int 2005 Jun; 95Suppl. 4: 29–36PubMedCrossRefGoogle Scholar
  59. 59.
    Flomax® (tamsulosin hydrochloride) capsules [package insert]. 2005 Oct 10 [online]. Available from URL: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServletser?.docBase=renetnt&folderPath=/Prescribing+Information/Pis/Flomax+Caps/Flomax.pdf [Accessed 2006 Mar 1]
  60. 60.
    Uroxatral® (alfuzosin hydrochloride) extended-release tablets [package insert]. 2003 Jun [online]. Available from URL: http://products.sanofi-aventis.us/uroxatral/uroxatral.html [Accessed 2006 Mar 1]
  61. 61.
    Hytrin® (terazosin hydrochloride) capsules [package insert]. 2001 Feb [online]. Available from URL: http://www.rxabbott.com/pdf/hytrin.pdf [Accessed 2006 Mar 1]
  62. 62.
    Cardura® (doxazosin mesylate) tablets [package insert]. 2002 Apr [online]. Available from URL: http://www.pfizer.com/pfizer/download/uspi_cardura.pdf [Accessed 2006 Mar 1]
  63. 63.
    Mikhailidis DP, Khan MA, Milionis HJ, et al. The treatment of hypertension in patients with erectile dysfunction. Curr Med Res Opin 2000; 16Suppl. 1: s31–6PubMedCrossRefGoogle Scholar
  64. 64.
    Kloner RA, Mullin SH, Shook T, et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol 2003 Aug; 170 (2 Pt 2): S46–50PubMedCrossRefGoogle Scholar
  65. 65.
    Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005 Dec 26; 96 (12B): 42M–6MPubMedCrossRefGoogle Scholar
  66. 66.
    Viagra® (sildenafil citrate) tablets [package insert]. 2005 Jul [online]. Available from URL: http://pfizer.com/pfizer/download/uspi_viagra.pdf [Accessed 2006 Mar 1]
  67. 67.
    Levitra® (vardenafil hydrochloride) tablets [package insert]. 2005 Jul [online]. Available from URL: http://www.fda.gov/cder/foi/label/2005/021400s0041bl.pdf [Accessed 2006 Mar 1]
  68. 68.
    Cialis® (tadalafil) tablets [package insert]. 2005Aug 26 [online]. Available from URL: http://pi.lilly.com/us/cialis-pi.pdf [Accessed 2006 Mar 1]
  69. 69.
    Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992 Oct 22; 327(17): 1185–91PubMedCrossRefGoogle Scholar
  70. 70.
    McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 Dec 18; 349(25): 2387–98PubMedCrossRefGoogle Scholar
  71. 71.
    Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995 Nov; 154(5): 1770–4PubMedCrossRefGoogle Scholar
  72. 72.
    Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 Sep; 60(3): 434–41PubMedCrossRefGoogle Scholar
  73. 73.
    Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003 Jan; 61(1): 119–26PubMedCrossRefGoogle Scholar
  74. 74.
    Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998 Sep; 34(3): 169–75PubMedCrossRefGoogle Scholar
  75. 75.
    Proscar® (finasteride) tablets [package insert]. 2006 Jan [online]. Available from URL: http://www.proscar.com/proscar/shared/documents/proscar_pi.pdf [Accessed 2006 Mar 1]
  76. 76.
    Avodart® (dutasteride) soft gelatin capsules [package insert]. 2005 May [online]. Available from URL: http://us.gsk.com/products/assets/us_avodart.pdf [Accessed 2006 Mar 1]
  77. 77.
    Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003 Feb; 61(2): 354–8PubMedCrossRefGoogle Scholar
  78. 78.
    Lowe FC, McConnell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003 Apr; 61(4): 791–6PubMedCrossRefGoogle Scholar
  79. 79.
    Vaughan Jr ED. Medical management of benign prostatic hyperplasia: are two drugs better than one? N Engl J Med 2003 Dec 18; 349(25): 2449–51PubMedCrossRefGoogle Scholar
  80. 80.
    Boyle P, Robertson C, Lowe F, et al. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 2004 Apr; 93(6): 751–6PubMedCrossRefGoogle Scholar
  81. 81.
    Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006 Feb 9; 354(6): 557–66PubMedCrossRefGoogle Scholar
  82. 82.
    Glemain P, Coulange C, Billebaud T, et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [in French]. Prog Urol 2002 Jun; 12(3): 395–403PubMedGoogle Scholar
  83. 83.
    Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002 May; 41(5): 497–506PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Department of UrologySt. Luke’s-Roosevelt HospitalNew YorkUSA
  2. 2.Department of UrologyColumbia University, College of Physicians and SurgeonsNew YorkUSA

Personalised recommendations